Added value of this study
The particularity of our study is to assess the safety and immunogenicity in humans of a DENV vaccine specifically designed to elicit a cytotoxic CD8+ T cell immune response, without inducing humoral immunity. The nanoparticle-based structure of PepGNP-Dengue is also innovative. Overall, the investigational vaccine appeared to be safe. Similar local reactogenicity, at least partly related to the vehicle, was recently described in another study with intradermal gold nanoparticles. PepGNP-Dengue did not induce significant humoral response against all four DENV serotypes–as expected–and elicited (or boosted) dengue-specific cellular immunity, primarily in participants in the low dose group.